ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 017

Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study

Tiffany Nguyen1, Ilaria Maccora1, Mekibib Altaye1, Wendy Haffey2, Theresa Hennard1, Alyssa Sproles1, Sherry Thornton1, Virginia Miraldi Utz1, Ken Greis2 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital, Cincinnati, OH, 2University of Cincinnati, Cincinnati, OH

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Biomarkers, Eye Disorders, Inflammation, Juvenile idiopathic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

Session Type: Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: Children diagnosed with oligoarticular juvenile idiopathic arthritis (JIA), the most commonly diagnosed subset of chronic arthritis, are at increased risk of developing uveitis. Known clinical risk factors such as JIA category, ANA positivity, ≤4 years JIA duration, and 6 years old at diagnosis are associated with increased risk but are not definitive. Regular ophthalmic screening is important since uveitis is asymptomatic. Tear fluid biomarkers are easily obtained specimens with great diagnostic potential. In this pilot study, we aim to identify potential tear-based inflammatory markers associated with uveitis development in children with JIA.

Methods: In this comparative cohort at Cincinnati Childrens with JIA-associated uveitis (JIA-U) and JIA without uveitis (JIA-no-U), participants were enrolled on the basis of high-risk factors: female, non-Hispanic, white and oligoarticular subtype. Medical charts were reviewed for demographics, uveitis characteristics, ophthalmic examination, and current treatment (Table 1). Tear fluid was collected in the left eye using Schirmer strips. We used advanced proteomic strategies (isobaric tag for relative quantitation [iTRAQ] labeling and nanoLC-MS/MS) to quantify and compare proteins in JIA-U and JIA-no-U. A P-value 0.1, based on Wilcoxon rank sum exact test, was considered significant.

Results: Fifteen proteins exhibited differences in tears of 5 children with JIA-U and 5 with JIA-no-U (Table 2). Of these, 9 showed a difference at p≤0.05. These proteins have been associated with inflammatory arthritis and general inflammatory response pathways. However, Keratin type II cytoskeletal 2 epidermal (KRT2), cathepsin D (CTSD), Ras-related C3 botulinum toxin substrate 1 (RAC1), C-1-tetrahydrofolate synthase, cytoplasmic (MTHFD1), Golgi apparatus protein 1 (GLG1), Heat shock 70 (HSPA1B), Aldo-keto reductase family 1 member C1(AKR1C1), Immunoglobulin heavy variable 3-49 (IGHV3-49), Adseverin (SCIN) and Immunoglobulin lambda variable 3-10 (IGLV3-10 ) demonstrated notably higher expression in tears of those with JIA-U (Table 2). These 10 proteins are associated with the immune response, specifically at the level of retinal pigment epithelium (RPE) and blood retinal barrier (BRB).

Conclusion: Uveitis is a vision-threatening disease that warrants exploration of avenues for early detection and treatment. The eye is an immune-privileged organ, immunologically shielded by the RPE as part of the BRB.Wehypothesize that the immune response proteins identified within the tears of JIA-U patients are byproducts of inflammation-induced RPE and BRB breakdown and furthers the inflammatory cascade. Tears of children with JIA-U and JIA-no-U display differential expression of protein biomarkers that may be a useful clinical source of potential onset of uveitis for those diagnosed with oligoarticular JIA. Furthermore, differential expression of ocular versus joint inflammation may provide insight in the pathogenesis of both JIA and uveitis. Further study in larger cohorts is needed to verify these results.

Supporting image 1

Supporting image 2


Disclosures: T. Nguyen: None; I. Maccora: None; M. Altaye: None; W. Haffey: None; T. Hennard: None; A. Sproles: None; S. Thornton: None; V. Miraldi Utz: None; K. Greis: None; S. Angeles-Han: None.

To cite this abstract in AMA style:

Nguyen T, Maccora I, Altaye M, Haffey W, Hennard T, Sproles A, Thornton S, Miraldi Utz V, Greis K, Angeles-Han S. Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/potential-uveitic-biomarkers-in-tears-of-children-with-juvenile-idiopathic-arthritis-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/potential-uveitic-biomarkers-in-tears-of-children-with-juvenile-idiopathic-arthritis-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology